S-1/A: DiamiR Biosciences Corp. Files Amendment No. 1 to Form S-1 for Initial Public Offering

DiamiR Biosciences Corp. amends its S-1 registration statement to revise disclosures in response to SEC comments for its upcoming IPO.

Summary

• DiamiR Biosciences Corp., a molecular diagnostics company, has filed an amendment to its Form S-1 registration statement.
• The amendment addresses comments received from the SEC.
• The company is planning an initial public offering of its common stock.
• The offering includes the resale of shares by selling shareholders.
• DiamiR Biosciences focuses on developing blood-based tests for neurodegenerative diseases.
• The company's lead product is CogniMIR, a test for early detection of Alzheimer's disease and mild cognitive impairment.
• The company has a limited operating history and has incurred net losses since inception.
• The company is an emerging growth company and intends to take advantage of reduced reporting requirements.
• The company's two co-founders currently own and control a combined 84.9% of the company's outstanding common stock.
• The company's European patent application for early diagnosis of amyotrophic lateral sclerosis (ALS) was granted by the European Patent Office on June 27, 2024.
• The company made an oral presentation at the 2024 Rett Syndrome Scientific Meeting on June 19, 2024.
• The company announced acceptance of its abstract for poster presentation at the 2024 International Alzheimers Association Conference (AAIC) on July 29, 2024.
• The company amended the convertible note with Kira Sheinerman, one of its founders and the Executive Director, such that the founder loaned us an additional $100,000 in March 2024.
• As of May 31, 2024, the Company was eligible to receive up to $0.5 million of additional funding to support qualified research and development expenses through August 2025 under the grants, subject to availability of funds and satisfactory progress, as determined by the NIH.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While it highlights the company's innovative technology and potential for growth, it also acknowledges the company's limited operating history, net losses, and the risks associated with the development and commercialization of its products.

Positives

• The company's European patent application for early diagnosis of amyotrophic lateral sclerosis (ALS) was granted by the European Patent Office on June 27, 2024.
• The company made an oral presentation at the 2024 Rett Syndrome Scientific Meeting on June 19, 2024.
• The company announced acceptance of its abstract for poster presentation at the 2024 International Alzheimers Association Conference (AAIC) on July 29, 2024.
• As of May 31, 2024, the Company was eligible to receive up to $0.5 million of additional funding to support qualified research and development expenses through August 2025 under the grants, subject to availability of funds and satisfactory progress, as determined by the NIH.

Negatives

• The company has a limited operating history and has incurred net losses since inception.
• The company's two co-founders currently own and control a combined 84.9% of the company's outstanding common stock.

Risks

• The company has a limited operating history, which makes it difficult to predict future prospects and financial performance.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company faces significant, evolving competition which, if not properly addressed, could adversely affect the business, results of operations, financial condition and price of the stock.
• The company's operations are dependent upon key personnel.
• The company will incur increased costs as a result of being a public company.
• The company has identified material weaknesses in its internal control over financial reporting which, if not corrected, could affect the reliability of its financial statements, and have other adverse consequences.
• The company's principal stockholders and management own a significant percentage of the capital stock and are able to exert a controlling influence over the business affairs and matters submitted to stockholders for approval, including a change in corporate control even if other shareholders wanted it to occur.
• If researchers, clinicians and healthcare administrators do not adopt the company's screening and diagnostic products, the company will not achieve future sales growth.
• New product development and clinical validation involves a lengthy and complex process, and the company may be unable to commercialize CogniMIR or any other products it may develop on a timely basis, or at all.
• The company relies on a sole supplier for some of the materials used in its tests and services, and it may not be able to find replacements or transition to alternative suppliers in a timely manner.
• The company may now or in the future be subject to laws and regulations relating to laboratory testing, which could materially adversely impact its ability to offer its products or services.
• The regulatory processes applicable to the company's products and operations are expensive, time-consuming, and uncertain and may prevent the company from obtaining required authorizations for the commercialization of its products.
• The company may be unable to protect or obtain proprietary rights.
• Intellectual property infringement claims by other companies could result in costly disputes and could limit the company's ability to sell its products.
• If product liability lawsuits are successfully brought against the company, it may incur substantial liabilities and may have to limit or cease sales of its products.
• There is no market for the securities offered hereby.
• The offering price and other terms of this offering have been arbitrarily determined and may not be indicative of future market prices.
• The market price of the common stock will fluctuate significantly in response to a variety of factors, some of which are beyond the company's control.
• Our management will have broad discretion in how we use the net proceeds of this offering and might not use them effectively.
• When this registration statement becomes effective, there will be a significant number of shares of Common Stock eligible for sale, which could depress the market price of such stock.
• Future sales of our securities may affect the market price of the Common Stock and result in material dilution.
• Any market that develops in shares of our common stock will be subject to the penny stock regulations and restrictions, which could impair liquidity and make trading difficult.
• We have established preferred stock which can be designated by our Board of Directors without shareholder approval.
• Anti-takeover provisions in our Certificate of Incorporation and our Bylaws, as well as provisions of Delaware law, might discourage, delay or prevent a change in control of our company or changes in our management and, therefore, depress the trading price of our common stock.

Future Outlook

The company expects to incur increased expenses as it conducts its clinical studies and creates additional infrastructure to develop and launch CogniMIR and support operations as a public company, and expects to continue to incur net losses and negative cash flows for the foreseeable future.

Industry Context

The company operates in the molecular diagnostics industry, which is intensely competitive. The market for molecular diagnostics is expected to grow rapidly in the coming years, driven by the increasing prevalence of chronic diseases and the growing demand for personalized medicine.

Comparison to Industry Standards

• The document mentions several companies working on biomarker tests for early detection of AD, including Quanterix, C2N Diagnostics, ALZPath, Cognoptix, Eli Lilly, LabCorp, NanoSomiX, NeuroTrack, Esya Labs, Brain Spec, Cogni.Dx, Roche, and Quest Labs.
• Quanterix, C2N Diagnostics, and Quest Labs have launched commercial LDTs for AD based on select protein biomarkers (A b 42/40, p-Tau217, and p-Tau181).
• The document states that the company is not aware of any companies offering commercial miRNA-based tests for brain health at this time.

Related Party Transactions

• Convertible promissory notes issued to Samuil R. Umansky and Kira Sheinerman.
• Insider stock purchase agreement with Kira Sheinerman.

Stakeholder Impact

• Shareholders: Dilution of ownership due to the issuance of new shares.
• Employees: Potential for job creation and career advancement as the company grows.
• Customers: Access to innovative blood-based tests for early detection and monitoring of neurodegenerative diseases.
• Suppliers: Increased demand for reagents and other supplies as the company expands its operations.
• Creditors: Increased risk of default if the company is unable to generate sufficient revenue to repay its debts.

Next Steps

• Initiate a clinical validation study in late 2024 from samples that have already been collected and are available to us from our freezer stock.
• Implement a robust commercial and publication strategy focused on securing coverage from Medicare and private insurance payors.
• Continue development of pipeline projects.
• Enhance lab throughput and capabilities.
• Scale up and enhance operations capabilities and working capital needs of the company.

Key Dates

Keywords

DiamiR Biosciences, IPO, CogniMIR, Alzheimer's disease, microRNA, molecular diagnostics, neurodegenerative diseases, clinical trials, biomarkers, LDT, FDA, CLIA, Rett syndrome, cancer, patent